Hepatocellular carcinoma risk assessment by measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals
Digestive and Liver Diseases Mar 05, 2018
Ravaioli F, et al. - The role of liver stiffness measurement (LSM) variation as a predictor of hepatocellular carcinoma (HCC) development was determined in patients treated with direct-acting antivirals (DAA). It was shown that Delta LS (ΔLS) is a beneficial non-invasive marker for speculating the HCC development after DAA treatment.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
